Psychostimulants and movement disorders.
Psychostimulants are a diverse group of substances with their main psychomotor effects resembling those of amphetamine, methamphetamine, cocaine or cathinone. Due to their potential as drugs of abuse, recreational use of most of these substances is illegal since the 1971 Convention on Psychotropic S...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-04-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fneur.2015.00075/full |
| _version_ | 1818515392707952640 |
|---|---|
| author | Andres eAsser Pille eTaba |
| author_facet | Andres eAsser Pille eTaba |
| author_sort | Andres eAsser |
| collection | DOAJ |
| description | Psychostimulants are a diverse group of substances with their main psychomotor effects resembling those of amphetamine, methamphetamine, cocaine or cathinone. Due to their potential as drugs of abuse, recreational use of most of these substances is illegal since the 1971 Convention on Psychotropic Substances. In recent years, new psychoactive substances have emerged mainly as synthetic cathinones with new molecules frequently complementing the list.Psychostimulant related movement disorders are a known entity often seen in emergency rooms around the world. These admissions are becoming more frequent as are fatalities associated with drug abuse. Still the legal constraints of the novel synthetic molecules are bypassed. At the same time chronic and permanent movement disorders are much less frequently encountered. These disorders frequently manifest as a combination of movement disorders. The more common symptoms include agitation, tremor, hyperkinetic and stereotypical movements, cognitive impairment, and also hyperthermia and cardiovascular dysfunction.The pathophysiological mechanisms behind the clinical manifestations have been researched for decades. The common denominator is the monoaminergic signaling. Dopamine has received the most attention but further research has demonstrated involvement of other pathways. Common mechanisms linking psychostimulant use and several movement disorders exist. |
| first_indexed | 2024-12-11T00:28:18Z |
| format | Article |
| id | doaj.art-e79c96635e714f15bac0098cceeadb12 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-11T00:28:18Z |
| publishDate | 2015-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-e79c96635e714f15bac0098cceeadb122022-12-22T01:27:28ZengFrontiers Media S.A.Frontiers in Neurology1664-22952015-04-01610.3389/fneur.2015.00075127637Psychostimulants and movement disorders.Andres eAsser0Pille eTaba1Tartu UniversityTartu UniversityPsychostimulants are a diverse group of substances with their main psychomotor effects resembling those of amphetamine, methamphetamine, cocaine or cathinone. Due to their potential as drugs of abuse, recreational use of most of these substances is illegal since the 1971 Convention on Psychotropic Substances. In recent years, new psychoactive substances have emerged mainly as synthetic cathinones with new molecules frequently complementing the list.Psychostimulant related movement disorders are a known entity often seen in emergency rooms around the world. These admissions are becoming more frequent as are fatalities associated with drug abuse. Still the legal constraints of the novel synthetic molecules are bypassed. At the same time chronic and permanent movement disorders are much less frequently encountered. These disorders frequently manifest as a combination of movement disorders. The more common symptoms include agitation, tremor, hyperkinetic and stereotypical movements, cognitive impairment, and also hyperthermia and cardiovascular dysfunction.The pathophysiological mechanisms behind the clinical manifestations have been researched for decades. The common denominator is the monoaminergic signaling. Dopamine has received the most attention but further research has demonstrated involvement of other pathways. Common mechanisms linking psychostimulant use and several movement disorders exist.http://journal.frontiersin.org/Journal/10.3389/fneur.2015.00075/fullMovement DisordersDrug abusepsychostimulant abusedrug induced disorderspsychostimulant toxicity |
| spellingShingle | Andres eAsser Pille eTaba Psychostimulants and movement disorders. Frontiers in Neurology Movement Disorders Drug abuse psychostimulant abuse drug induced disorders psychostimulant toxicity |
| title | Psychostimulants and movement disorders. |
| title_full | Psychostimulants and movement disorders. |
| title_fullStr | Psychostimulants and movement disorders. |
| title_full_unstemmed | Psychostimulants and movement disorders. |
| title_short | Psychostimulants and movement disorders. |
| title_sort | psychostimulants and movement disorders |
| topic | Movement Disorders Drug abuse psychostimulant abuse drug induced disorders psychostimulant toxicity |
| url | http://journal.frontiersin.org/Journal/10.3389/fneur.2015.00075/full |
| work_keys_str_mv | AT andreseasser psychostimulantsandmovementdisorders AT pilleetaba psychostimulantsandmovementdisorders |